https://www.socictopen.socict.org/files/original/365ab9bd8c33f768633b99014b68863b.pdf 9b858bf982619511440e772ef12ebe9d Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics Creator An entity primarily responsible for making the resource Md. Sahab Uddin, Jawaher A. Abdulhakim, Md. Sahab Uddin, May N. Bin-Jumah, Md. Farhad Hossain, Md. Farhad Hossain, Lotfi Aleya, Mohamed M. Abdel-Daim, Ghulam Md. Ashraf, Simona G. Bungǎu, Ghulam Md Ashraf, Md. Tanvir Kabir, Md. Asraful Alam, Mohamed M. Abdel-Daim Description An account of the resource In December 2019, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related epidemic was first observed in Wuhan, China. In 2020, owing to the highly infectious and deadly nature of the virus, this widespread novel coronavirus disease 2019 (nCOVID-19) became a worldwide pandemic. Studies have revealed that various environmental factors including temperature, humidity, and air pollution may also affect the transmission pattern of COVID-19. Unfortunately, still, there is no specific drug that has been validated in large-scale studies to treat patients with confirmed nCOVID-19. However, remdesivir, an inhibitor of RNA-dependent RNA polymerase (RdRp), has appeared as an auspicious antiviral drug. Currently, a large-scale study on remdesivir (i.e., 200 mg on first day, then 100 mg once/day) is ongoing to evaluate its clinical efficacy to treat nCOVID-19. Good antiviral activity against SARS-CoV-2 was not observed with the use of lopinavir/ritonavir (LPV/r). Nonetheless, the combination of umifenovir and LPV/r was found to have better antiviral activity. Furthermore, a combination of hydroxychloroquine (i.e., 200 mg 3 times/day) and azithromycin (i.e., 500 mg on first day, then 250 mg/day from day 2–5) also exhibited good activity. Currently, there are also ongoing studies to evaluate the efficacy of teicoplanin and monoclonal and polyclonal antibodies against SARS-CoV-2. Thus, in this article, we have analyzed the genetic diversity and molecular pathogenesis of nCOVID-19. We also present possible therapeutic options for nCOVID-19 patients. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource SARS-CoV-2, favipiravir, Remdesivir, immunomodulators, ncovid-19, RdRp inhibitors Identifier An unambiguous reference to the resource within a given context 10.3389/fcell.2020.00616 Source A related resource from which the described resource is derived Epidemiology and Health Publisher An entity responsible for making the resource available Korean Society of Epidemiology Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Biology (General)